<DOC>
	<DOCNO>NCT00660036</DOCNO>
	<brief_summary>The purpose study investigate combination gemtuzumab ozogamicin , mitoxantrone etoposide second line therapy patient acute myeloid leukemia .</brief_summary>
	<brief_title>Phase I/II Study Mitoxantrone , Etoposide Gemtuzumab Ozogamicin Acute Myeloid Leukemia</brief_title>
	<detailed_description>The combination mitoxantrone etoposide active regimen refractory/relapsed AML patient . In order improve efficacy mitoxantrone etoposide second line therapy patient AML propose conduct phase I/II clinical trial combine gemtuzumab ozogamicin mitoxantrone etoposide . The phase I portion trial determine maximum tolerate dose gemtuzumab ozogamicin combine mitoxantrone etoposide phase II portion trial determine efficacy safety combine regimen patient AML .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Able understand ability provide write consent Between 18 70 year age Patients CD33 positive ( determined CD33 expression ≥ 20 % leukemic blast ) de novo AML respond first line induction therapy ECOG Performance Status 02 Patients must follow laboratory value within 48 hour prior begin protocol treatment : Serum creatinine ≤ 1.5 mg/ml calculate creatinine clearance ≥ 50mL/min ( use CockcroftGault equation ) ; AST ≤ 59 IU/L ; ALT ≤ 72 IU/L ; Total bilirubin ≤ 1.3 mg/ml ; Note : Hematologic abnormality use criterion entry exclusion . Patients must leave ventricular ejection fraction ( LVEF ) ≥50 % Females childbearing potential must negative pregnancy test screen subject must agree use effective method contraception . Patients acute promyelocytic leukemia Prior use mitoxantrone etoposide gemtuzumab ozogamicin Antecedent hematologic disorder precede initial presentation AML therapy related AML History thromboembolic event within past 12 month Hepatitis B C HIV positive serology Symptomatic central nervous system ( CNS ) involvement History congestive heart failure Myocardial infarction past 6 month Uncontrolled , lifethreatening infection respond antimicrobial therapy History psychiatric disorder may compromise compliance protocol allow appropriate inform consent Patient may receive anti neoplastic investigational agent INR &gt; 1.5 patient receive systemic anticoagulation ( e.g warfarin ) Patient undergone autologous allogeneic stem cell transplantation Other active malignancy except nonmelanoma skin cancer cervical intraepithelial neoplasia Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Second line</keyword>
	<keyword>Gemtuzumab ozogamicin</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase II</keyword>
</DOC>